The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

The GOP senator objected to Secretary Kennedy's recasting of the influential advisory panel, which has sparked criticism from ...

The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug ...

Jaqueline Corrigan-Curay, who serves as acting head of the FDA’s Center for Drug Evaluation and Research, will depart next ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

GLP-1 therapies primarily use single-use injectable pens, contributing to medical waste challenges. The pharmaceutical ...

Illumina expects that adding SomaLogic will aid its “multiomics” business strategy and strengthen the value of its gene ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...